INNOVATIONS THAT CHANGE

EVERYTHING

“S2Medical AB (publ) is a Nasdaq-listed Swedish biomed-tech innovator active in wound healing, infection control and cosmeceuticals. Harnessing biomaterials, antimicrobial peptides, and regenerative medicine, we develop cutting-edge solutions like Epiprotect®, IvaQ™, Instagraft®, ADMERCIN®, and Symbiovance™ to accelerate healing, fight resistant bacteria, and advance the field of cosmeceuticals.”
— Petter SivlĂ©r, CEO

Technologies

  • Epiprotect


    Epiprotect is an innovative technology designed to protect and support wound healing by creating an optimal environment for tissue recovery. Its unique design reduces the risk of infection and pain while accelerating the healing process. The technology has now been acquired by ABENA, a family-owned, world-leading healthcare company known for its high quality, global presence, and expertise in healthcare solutions. S2Medical remains deeply involved in the production and continued growth of Epiprotect.

  • ivaQ


    IvaQ is an advanced negative pressure therapy system designed to effectively manage deep wounds and surgical incisions while promoting the formation of granulation tissue—crucial for closing deep wounds. With its unique, patented absorbent tubing, IvaQ enables smoother treatment by reducing the need for unnecessary dressing changes. The compact, portable, single-use system ensures easy and convenient application, making it an ideal solution for both healthcare providers and patients in need of effective wound care for complex wounds and surgical procedures.

  • ADMERCIN


    ADMERCIN is an innovative technology designed to combat infections caused by multiresistant bacteria, one of modern medicine’s greatest challenges. By utilizing powerful antimicrobial peptides (AMPs), ADMERCIN targets bacteria on multiple levels, enabling even previously ineffective antibiotics to eliminate resistant strains. This groundbreaking solution opens new possibilities for treating infections that were once difficult to manage, setting a new standard in the fight against antibiotic resistance.

How it all started?

S2Medical was founded in 2013 with a mission to revolutionize wound care and medical innovation. Through cutting-edge research and collaborations with top universities, we developed groundbreaking solutions that enhance healing, combat infections, and advance cosmetic treatments.

One of our key innovations, Epiprotect, redefined wound healing by creating an optimal recovery environment. It reduces pain, lowers infection risk, and accelerates tissue regeneration. Now acquired by ABENA, a world-leading healthcare company, Epiprotect continues to grow, with S2Medical remaining deeply involved in its production and development.

Research & Development

Innovation is at the core of S2Medical. Our R&D team operates at the forefront of biomaterials, regenerative medicine, and infection control, developing next-generation solutions for wound healing, skin restoration, and cosmeceuticals. Through interdisciplinary collaborations with leading universities and researchers, we push scientific boundaries to create safer, more effective treatments.

From pioneering epidermal substitutes to antimicrobial peptides (AMPs) designed to combat multiresistant bacteria, our work bridges medicine and biotechnology. Every breakthrough is driven by a commitment to evidence-based innovation, ensuring our technologies meet the highest medical standards while improving lives worldwide.